Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



The Fertility Show






Free fetal DNA for non-invasive prenatal diagnosis (NIPD): ethical aspects

16 June 2008

By Dr Zuzana Deans and Dr Ainsley Newson

Centre for Ethics in Medicine, University of Bristol

Appeared in BioNews 462
Dr Phillipa Brice's accompanying commentary highlights how non-invasive testing of free fetal DNA (ffDNA) in pregnancy could transform women's experiences of antenatal screening and prenatal diagnosis. NIPD is already available for foetal sex, rhesus D blood type and some Mendelian inheritance such as achondroplasia, with tests for aneuploidy detection and Down syndrome being developed. These tests will not pose a risk to the pregnancy and could provide women and couples with definitive information earlier than current methods. The advantages over 'traditional' prenatal screening and diagnosis seem obvious - so is NIPD ethically problematic?

Unsurprisingly, a pithy 'yes' or 'no' answer to this question is impossible and would undermine the opportunity for a rich and important discussion of how the ethics of NIPD might depart from 'traditional' testing in pregnancy. But in short, expectations are that NIPD can be conducted ethically if the right conditions are in place, and it is laudable that those working in this field are liaising so closely with ethicists to address emerging concerns as this technology develops.(1)

An initial question is whether this technology gives rise to any new ethical questions over and above existing screening, diagnostic or assisted reproductive technologies. Existing debates in prenatal diagnosis, such as the disability rights critique, will continue to be relevant and may be exacerbated. So too will issues of the 'seriousness' threshold for offering PND and the routinisation of testing. Whilst NIPD does not depart too far from these existing issues, there may be important changes to the moral landscape of testing.

If offered widely (for suitable conditions), NIPD will effectively become a screening test with a definitive outcome, akin to HIV (human immunodeficiency virus) testing in pregnant women, but one that may lead to termination. We need to decide which method of consent is appropriate and be mindful that a major justification for declining prenatal diagnosis (risk to the pregnancy) will be removed. Overall termination rates may also increase. Women will need sound and unbiased information about NIPD and will require time to reflect before deciding about testing.

Women are generally expected to enter into prenatal testing as fully consenting individuals. While at face value this may seem an obvious condition for ethical conduct, achieving informed consent or following an informed choice may not be as straightforward as it first appears. This may be especially true in the context of NIPD. Research shows that there are different attitudes between cultures as to whether women, couples or health professionals should make decisions about prenatal testing (2). This arguably calls into question the emphasis on respect for individual autonomy so common in Northern European nations. Our research is asking whether autonomous decision-making for NIPD might better be understood in a feminist (relational) way, recognising social relationships as a fundamental part of what it is for an individual to make an autonomous decision.

NIPD could also be used for non-medical ends, such as sex determination and paternity testing. Indeed, internet-based providers of both are already available. Whilst a full exploration of these issues is not possible here, such applications should be monitored. For example, one major concern is that sex determination may be used to reinforce stereotyped gender expectations or sex discrimination. Prenatal paternity testing to inform the interested parties may be acceptable, but procuring this test to terminate if the 'wrong' biological father is discovered is more challenging.

These concerns mean that procedures and regulation for NIPD should be considered. Prenatal diagnosis currently involves clinical services as gatekeepers but NIPD will only require a blood test - should this be regulated by the market or more formally? Any new guidelines should be consistent with current practice and should not unduly restrict professional autonomy.

Ethical analysis of NIPD should go hand in hand with economic and clinical evaluations, not to mention empirical research with pregnant women, couples and health professionals. This multi-disciplinary approach will help address important questions such as educational and informational needs, and psycho-social indications. We are currently working with the SAFE Network (3) and the Public Health Genetics Foundation to deliberate ethical issues. NIPD is certainly not without ethical pitfalls, but early identification and deliberation will ensure a constructive role for NIPD to facilitate pregnant women to make well informed decisions in pregnancy, with good informational support.

 

SOURCES & REFERENCES
1) Newson AJ (2008) Ethical aspects arising from non-invasive fetal diagnosis.
Semin Fetal Neonatal Med. 13(2):103-8 |
 
2) van den Heuvel A, Dormandy E, Chitty L, Newson A, Ma R, Masturzo B, Pajkrt E & Marteau  T. 'Is informed choice in prenatal testing universally valued? A population based survey in Europe and Asia' (submitted).
|
 
|
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

25 March 2013 - by Dr Colin Gavaghan 
Being a bioethicist in the Antipodes is becoming a dangerous business these days. Just over a year ago, the publication, by two Australian academics, of a paper exploring the acceptability of 'post-birth abortion' led to media furore, hate mail and even death threats to the authors... [Read More]
11 June 2012 - by Dr Daniel Grimes 
Researchers have sequenced the entire genome of an 18 and a half-week-old fetus using DNA samples from the blood of its mother and saliva samples from its father. These findings provide a proof of principle that a fetus can be examined for genetic defects using non-invasive technologies... [Read More]
15 August 2011 - by Rose Palmer 
A simple blood test for pregnant women can accurately predict the sex of a fetus at seven weeks, much earlier than conventional techniques, new research has found. A systematic review and meta-analysis examined the results of 57 earlier studies that included more than 6,500 pregnancies... [Read More]
16 February 2009 - by Dr Philippa Brice 
Cell-free fetal nucleic acids - DNA or the related molecule RNA - are present in the blood. As has previously been reviewed, the discovery that a small proportion of the cell-free nucleic acids in the mother's blood during pregnancy actually comes from the fetus paved the way for new techniques to exploit... [Read More]
13 October 2008 - by Lorna Stewart 
Scientists at Stanford University in California, US have developed a new non-invasive prenatal test for Down's syndrome. Stephen Quake and colleagues successfully identified presence and absence of fetal chromosomal abnormality in 18 pregnant women from maternal blood samples. The work is published this month in the journal... [Read More]

16 June 2008 - by Dr Philippa Brice 
Antenatal care in the UK includes various forms of screening intended to assess the health of the mother and fetus; at present this includes the use of ultrasound imaging to check on physical development of the fetus, and serum screening using maternal blood to determine blood group, identify the presence... [Read More]
06 February 2007 - by Dr Jess Buxton 
A new study offers 'proof of principle' for a non-invasive pregnancy test that can detect conditions such as Down syndrome using samples of the mother's blood. The findings, published online in the Lancet journal, show that the technique correctly diagnosed 58 out of 60 samples, with... [Read More]
25 September 2006 - by Dr Jess Buxton 
Non-invasive prenatal tests to identify fetuses at risk of genetic disorders as early as the sixth week of pregnancy are now a reality, say British scientists. A team based at the Institute of Child Health in London and Bristol has successfully carried out simple blood tests... [Read More]
06 October 2005 - by BioNews 
Scientists based at Hong Kong University have found a way to identify traces of fetal DNA in a pregnant woman's blood, bringing non-invasive prenatal testing a step closer. The researchers, who published their findings in the Proceedings of the National Academy of Sciences, have developed a new technique for distinguishing... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
PET CONFERENCE
COMMERCIALISATION OF LIFE


Lord Robert Winston, Professor of Science and Society at Imperial College London and speaker at the Progress Educational Trust's conference 'The Commercialisation of Life', taking place in central London on Tuesday 2 December

London, 2 December
Click HERE for details

FREE EVENT
HOW SHOULD YOUR DNA BE USED IN THE 100,000 GENOMES PROJECT?


'Genetic Conditions: How Should Your DNA Be Used in the 100,000 Genomes Project?', a FREE public event being organised by the Progress Educational Trust in central London on the evening of Thursday 6 November 2014

London, 6 November
Click HERE for details

Good Fundraising Code

Advertise your products and services HERE - click for further details